Deals In Depth: November 2013

Egalet secured Shionogi as its first major partner in a deal focused on abuse-deterring forms of hydrocodone; to complement its specialty pharmacy portfolio, CVS acquired the infusion therapy business Coram for $2.1 billion. A $729 million debt offering by Incyte made up nearly one-third of the $2.5 billion in biopharma financing; and sources of public fundraising have been increasing over the past few months in the device industry, which raised $532 million.